Cargando…

Mutation profiles in circulating cell‐free DNA predict acquired resistance to olaparib in high‐grade serous ovarian carcinoma

Although resistance to poly(ADP‐ribose) polymerase inhibitors (PARPi) has gradually become a major challenge in the maintenance therapy for high‐grade serous ovarian carcinoma (HGSOC), there are no universal indicators for resistance monitoring in patients. A key resistance mechanism to PARPi is the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Dianxing, Guo, Ensong, Yang, Bin, Qin, Xu, Fu, Yu, Fan, Junpeng, Zhuang, Xucui, Yao, Qianqian, Lu, Funian, Li, Wenting, Xiao, Rourou, Wu, Xue, Yang, Xiaohang, Wang, Zizhuo, Liu, Chen, You, Lixin, Zang, Rongyu, Zhou, Qi, Zhao, Weidong, Chen, Gang, Sun, Chaoyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357630/ https://www.ncbi.nlm.nih.gov/pubmed/35661486 http://dx.doi.org/10.1111/cas.15456

Ejemplares similares

MRE11:p.K464R mutation mediates olaparib resistance by enhancing DNA damage repair in HGSOC
por: Zhuang, Xucui, et al.
Publicado: (2023)

Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis
por: Yang, Bin, et al.
Publicado: (2022)

STAT4, a potential predictor of prognosis, promotes CD8 T‑cell infiltration in ovarian serous carcinoma by inducing CCL5 secretion
por: Wang, Wei, et al.
Publicado: (2023)

Clinical and molecular characteristics of COVID-19 patients with persistent SARS-CoV-2 infection
por: Yang, Bin, et al.
Publicado: (2021)

The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer
por: Liu, Chen, et al.
Publicado: (2022)

Impact of chemotherapy and immunotherapy on the composition and function of immune cells in COVID-19 convalescent with gynecological tumors
por: Qin, Tianyu, et al.
Publicado: (2021)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer
por: Xiao, Rourou, et al.
Publicado: (2022)

Fecal microbiota transplantation mitigates vaginal atrophy in ovariectomized mice
por: Huang, Jia, et al.
Publicado: (2021)

WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway
por: Guo, Ensong, et al.
Publicado: (2021)

Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis
por: Meng, Yifan, et al.
Publicado: (2020)

Integrating pathology, chromosomal instability and mutations for risk stratification in early-stage endometrioid endometrial carcinoma
por: Li, Yuan, et al.
Publicado: (2020)

Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer
por: Nakamura, Kohei, et al.
Publicado: (2020)

Metagenomic analysis of the microbiome of the upper reproductive tract: combating ovarian cancer through predictive, preventive, and personalized medicine
por: Qin, Xu, et al.
Publicado: (2022)

MS: Wip1 suppresses angiogenesis through the STAT3-VEGF signalling pathway in serous ovarian cancer
por: Yin, Sheng, et al.
Publicado: (2022)

Correction: Wip1 suppresses angiogenesis through the STAT3-VEGF signalling pathway in serous ovarian cancer
por: Yin, Sheng, et al.
Publicado: (2022)

Multi-omics characterization of silent and productive HPV integration in cervical cancer
por: Fan, Junpeng, et al.
Publicado: (2023)

Real‐world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau
por: Cao, Yabing, et al.
Publicado: (2019)

Harnessing preclinical models for the interrogation of ovarian cancer
por: Qin, Tianyu, et al.
Publicado: (2022)

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
por: Ledermann, Jonathan A, et al.
Publicado: (2016)

Tolerance of Olaparib in a Patient With Unresectable Serous Gynecologic Cancer and End-Stage Renal Disease
por: Goon, Kelsey C, et al.
Publicado: (2023)

BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages
por: Li, Xi, et al.
Publicado: (2020)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
por: Lampert, Erika J., et al.
Publicado: (2019)

Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China
por: Jiang, Yi, et al.
Publicado: (2023)

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
por: Dougherty, Brian A., et al.
Publicado: (2017)

Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study
por: Paik, E Sun, et al.
Publicado: (2019)

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
por: Gao, Qinglei, et al.
Publicado: (2022)

Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance
por: Cahuzac, Maxime, et al.
Publicado: (2022)

Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
por: Inoue, Kayo, et al.
Publicado: (2020)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
por: Wu, Min, et al.
Publicado: (2018)

Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer
por: Stanzione, Marcello, et al.
Publicado: (2022)

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
por: Friedlander, Michael, et al.
Publicado: (2018)

KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer
por: Zhao, Haiyue, et al.
Publicado: (2016)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

The combination of olaparib and camptothecin for effective radiosensitization
por: Miura, Katsutoshi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sn3lg3uc6me4etssb9g0b0kg1i